References
- Biktasova AK, Dudimah DF, Uzhachenko RV, Park K, Akhter A, Arasada RR, Evans JV, Novitskiy SV, Tchekneva EE, Carbone DP et al. Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy. Cancer Res 2015; 75(22):4728-41; PMID:26404003; http://dx.doi.org/10.1158/0008-5472.CAN-14-1154.
- Thounaojam MC, Dudimah DF, Pellom ST, Jr., Uzhachenko RV, Carbone DP, Dikov MM, Shanker A. Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-kappaB crosstalk. Oncotarget 2015; 6:32439-55; PMID:26431276; http://dx.doi.org/10.18632/oncotarget.5857
- Shanker A, Pellom ST, Dudimah DF, Thounaojam MC, de Kluyver RL, Brooks AD, Yagita H, McVicar DW, Murphy WJ, Longo DL et al. Bortezomib improves adoptive T cell therapy by sensitizing cancer cells to FasL cytotoxicity. Cancer Res 2015; 75(24):5260-72; PMID:26494122; http://dx.doi.org/10.1158/0008-5472.CAN-15-0794
- Minter LM, Osborne BA. Canonical and non-canonical Notch signaling in CD4(+) T cells. Curr Top Microbiol Immunol 2012; 360:99-114; PMID:22695917; http://dx.doi.org/10.3389/fimmu.2014.00054
- Ayaz F, Osborne BA. Non-canonical notch signaling in cancer and immunity. Front Oncol 2014; 4:345; PMID:25538890; http://dx.doi.org/10.3389/fonc.2014.00345
- Radtke F, Fasnacht N, Macdonald HR. Notch signaling in the immune system. Immunity 2010; 32:14-27; PMID:20152168; http://dx.doi.org/10.1016/j.immuni.2010.01.004
- Lobry C, Oh P, Aifantis I. Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med 2011; 208:1931-5; PMID:21948802; http://dx.doi.org/10.1084/jem.20111855
- Huang Y, Lin L, Shanker A, Malhotra A, Yang L, Dikov MM, Carbone DP. Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth. Cancer Res 2011; 71:6122-31; PMID:21825014; http://dx.doi.org/10.1158/0008-5472.CAN-10-4366
- Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005; 23:2556-68; PMID:15767641; http://dx.doi.org/10.1200/JCO.2005.07.799
- Wang Y, Schmid-Bindert G, Zhou C. Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians. Ther Adv Med Oncol 2012; 4:19-29; PMID:22229045; http://dx.doi.org/10.1177/1758834011427927